Rhythm Biosciences Ltd. confirmed another milestone toward commercialisation of its colorectal cancer blood test, with the announcement of the final ColoSTAT® clinical trial site closure. The closure of all ColoSTAT® clinical trial sites signifies the finality of clinical trial operations, which follows the recent announcement confirming ColoSTAT® delivers very high accuracy for the detection of colorectal cancer, recording a sensitivity1 of 81% and a specificity2 of 91%. The Company is now in the process of completing remaining regulatory submission activities.

Near-term activities ahead of the market release of ColoSTAT® later this year, include: Final clinical study report completion; Partnering /commercialisation deals (Domestic and International); International country submissions /registration updates; and Submission with the Therapeutic Goods Administration (TGA).